Loading
A phase 3 trial of afatinib in lung cancer, run by Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., now recruiting.
FHND9041 Versus Afatinib for Non-small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT06759857 by Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., with a registry enrolment figure of 350 participants, started 2021-08-01 and due to reach its primary completion in 2025-03-04. Interventions recorded: FHND9041; Afatinib. Conditions listed: Non Small Cell Lung Cancer. Primary outcome: Progression-Free Survival (PFS). Lung eligibility wording from the registry: "* Histologically or cytologically confirmed diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC), including patients with recurrent disease following prior surgical treatment or newly diagnosed Stage IIIb, IIIc, or IV NSCLC (staging based on the 8th edition of the AJCC guid". Sites: China. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.